Supraglottic cancer is a main type of laryngeal carcinoma, which is one of the most common head and neck tumors. Cervical nodal metastasis is an important prognostic factor in supraglottic cancer. Current management, following the US National Comprehensive Cancer Network guidelines for T1-2, N0 supraglottic cancer (NCCN 2017), is either definitive radiotherapy or primary surgery with or without neck dissection. The optimal neck treatments strategy remains unclear in clinical settings owing to the limitation of a small number of retrospective studies and a lack of prospective trials. The investigators conducted a prospective, randomised trial to compare radiotherapy with neck dissection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
158
Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
Tianjin Medical University Cancer Institute and Hopital
Tianjin, Tianjin Municipality, China
Neck control rates
The percentage of patients without cervical lymph node metastasis
Time frame: 2 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 1 year
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 2 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 3 years
Disease-free survival
The proportion of patients did not find clear evidence of recurrence or metastasis
Time frame: 5 years
Overall survival
The proportion of patients who survived
Time frame: 3 years
Overall survival
The proportion of patients who survived
Time frame: 5 years
Quality of life (EORTC QLQ-C30)
Evaluated by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
Time frame: 1 year
Quality of life (EORTC QLQ-HN35)
Evaluated by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-HN35
Time frame: 1 year
Treatment cost
The total cost of the treatment of the primary and cervical lymph nodes until the discharge
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.